Tandem Diabetes Care (TNDM) Current Deferred Revenue (2013 - 2026)

Tandem Diabetes Care has reported Current Deferred Revenue for 14 years, with the latest figure at $9.0 million in Q1 2026.

• For the quarter ending Q1 2026, Current Deferred Revenue fell 18.43% year-over-year to $9.0 million; the trailing twelve-month figure through Mar 2026 stood at $9.0 million (down 18.43% YoY), and the FY2025 full-year result was $9.5 million, down 19.47% from the prior year.
• Current Deferred Revenue for Q1 2026 stood at $9.0 million, down from $9.5 million in the prior quarter.
• The five-year high for Current Deferred Revenue was $44.0 million in Q4 2023, with the low at $1.1 million in Q1 2024.
• Historically, Current Deferred Revenue has averaged $16.5 million across 5 years, with a median of $11.7 million in 2022.
• Annual changes were most pronounced in 2024 — Current Deferred Revenue sank 95.3% — and 2025, when it surged 897.91%.
• Tandem Diabetes Care's Current Deferred Revenue stood at $18.8 million in 2022, then jumped by 133.55% to $44.0 million in 2023, then plunged by 73.11% to $11.8 million in 2024, then retreated by 19.47% to $9.5 million in 2025, then slipped by 6.01% to $9.0 million in 2026.
• The last three Current Deferred Revenue figures came in at $9.0 million (Q1 2026), $9.5 million (Q4 2025), and $9.8 million (Q3 2025), per Business Quant data.